Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Heatmap
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TBPH
#2568
Theravance Biopharma, Inc.
16.630
0
USD
+0.18%
Setor:
Cuidados de saúde
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
+0.18%
Mudança mensal
+19.30%
Mudança em 6 meses
+15.89%
Mudança anual
+15.89%
Fechamento anterior
16.600
0
Abrir
16.580
0
Bid
Ask
Mínimo
16.575
0
High
16.640
0
Volume
262
Mercados
Ações
Cuidados de saúde
TBPH
Abrir gráfico completo
Financials
Visão geral
Relatórios
Estatísticas
Trimestral
Ano
Valor
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
49.47 M
50 M
50.36 M
50.67 M
51.49 M
—
Valuation ratios
Enterprise value
427.72 M
335.9 M
273.56 M
565.04 M
795.63 M
1.97 B
Price to earnings ratio
-8.18
-7.57
45.96
25.61
9.08
73.09
Price to sales ratio
7.14
6.71
7.1
9.15
8.97
31.93
Price to cash flow ratio
-39.85
13.72
2.28
3.03
4.04
23.06
Price to book ratio
2.62
0.61
0.73
0.92
3.25
5.5
Enterprise value to EBITDA ratio
-9.8
-6.93
-7.7
-18.13
-1 671.48
-1 704.24
Profitability ratios
Return on assets %
-0.04
-0.04
0.13
0.01
0.13
0.22
Return on equity %
-0.09
-0.08
0.24
0.02
0.21
0.38
Return on invested capital %
-25.43
-24.24
-5.71
41.13
58.52
69.7
Gross margin %
100
100
100
100
100
400
Operating margin %
-49.06
-93.8
-10.4
-32.29
43.61
-92.89
EBITDA margin %
-46.81
-91.12
-8.84
-30.27
44.48
-85.75
Net margin %
-82.79
-88.24
209.33
18.08
132.98
272.15
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
5.02
4.77
6.7
9.48
10.93
31.88
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.05
0.04
0.07
0.05
0.1
0.26
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.02
0.87
4.1
-0.13
-0.12
4.72
EBIT per share
-0.19
-0.29
-0.05
-0.12
0.39
-0.08
EBITDA per share
-0.18
-0.28
-0.05
-0.12
0.4
-0.05
Total debt per share
—
—
—
—
—
—
Cash per share
1.81
2.63
6.68
6.35
6.12
21.79
Net current asset value per share
3.3
3.02
7.22
6.83
8.12
25.2
Tangible book value per share
3.59
3.34
4.43
4.48
5.76
18.02
Working capital per share
2.64
2.39
6.14
6.11
7.38
22.03
Book value per share
3.59
3.34
4.43
4.48
5.76
18.02
Notícias
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
TD Cowen eleva preço-alvo da Theravance Biopharma com foco em fluxo de caixa
Theravance's Q4 Earnings and Revenues Miss Estimates
BTIG reitera classificação de compra para Theravance Biopharma após receita superar expectativas
Lucro da Theravance Biopharma superou projeções por $0,15; receita menor do que estimativas
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Assertio (ASRT) Reports Q4 Loss, Beats Revenue Estimates
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
Oppenheimer rebaixa ações da Theravance Biopharma após falha na Fase 3
Oppenheimer downgrades Theravance Biopharma stock rating on Phase 3 miss
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study